The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro

Blood

Volumn 101, Issue 7, 2003, Pages 2454-2460

  Pepper, Chris ^a   Thomas, Alun ^b   Hoy, Terry ^b   Milligan, Donald ^b   Bentley, Paul ^b   Fegan, Chris ^b  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE INHIBITOR; COLECALCIFEROL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P21; PROTEIN P53; SEOCALCITOL; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; ANTINEOPLASTIC AGENT; CALCITRIOL; DRUG DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CELL LINEAGE; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LD 50; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; CASE CONTROL STUDY; CELL CYCLE; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCITRIOL; CASE-CONTROL STUDIES; CELL CYCLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038107401     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-1984     Document Type: Article

References (40)

1. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol. 1998;25:11-18.
2. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukemia. Br J Haematol. 1996;95:513-517.
3. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10:456-459.
4. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 1996;69:114-119.
5. Pepper C, Hoy T, Bentley P. Bcl-2/Bax ratios in chronic lymphocytic leukemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 1997;76:935-938.
6. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med. 1989;320:980-991.
7. Hansen CM, Hamberg KJ, Binderup E, Binderup L. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential: background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des. 2000;6:803-828.
8. 3 receptors in human leukocytes. Science. 1983;221:1181-1183.
9. 3 receptors: gene regulation and genetic circuitry. FASEB J. 1988;2:3043-3053.
10. 3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol. 1984;98:391-398.
11. 2 vitamin D3-regulated expression of the eukaryotic genome. Nutr Rev. 1994;52:376-382.
12. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998;13:325-349.
13. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev. 1995;16:200-257.
14. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibitors of cell growth in culture. Endocdnology. 1981;108:1083-1086.
15. Frampton RJ, Omond SA, Eisman JA. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. Cancer Res. 1983;43:4443-4447.
16. Brehier A, Thomasset M. Human colon cell line HT-29: characterisation of 1,25-dihydroxyvitamin D3 receptor and induction of differentiation by the hormone. J Steroid Biochem. 1988;29:265-270.
17. James SY, Mackay AG, Colston KW. Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol. 1995;54:391-394.
18. Elstner E, Linker-Israeli M, Umiel T, et al. Combination of a potent 20-epi vitamin D3 analogue (KH10060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukaemia cells. Cancer Res. 1996;56:3570-3576.
19. Mathiasen IS, Colston KW, Binderup L. EB1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem Mol Biol. 1993;46:365-371.
20. James SY, Mackay AG, Binderup L, Colston KW. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen responsive growth of human breast cancer cells. J Endocrinol. 1994;141:555-563.
21. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
22. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206.
23. Pepper C, Thomas A, Hoy T, Bentley P. Chlorambucil resistance in B-cell chronic lymphocytic leukemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. Br J Haematol. 1999;104:581-588.
24. Pepper C, Hooper K, Thomas A, Hoy T, Bentley P. Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chrorambucil in B-cell chronic lymphocytic leukaemia cells. Leuk Lymphoma. 2001;42:491-498.
25. Ferlini C, Di Cesare S, Rainaldi G, et al. Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry. 1996;24:106-115.
26. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184:39-51.
27. Park WH, Seol JG, Kim ES, et al. Induction of apoptosis by vitamin D3 analogue EB1089 in NCl-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol. 2000;109:576-583.
28. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379-3389.
29. Jaiswal AS, Narayan S. SN2 DNA-alkylating agent-induced phosphorylation of p53 and activation of p21 gene expression. Mutat Res. 2002;500:17-30.
30. Stankovic T, Stewart GS, Fegan C, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unpaired chromosome damage. Blood. 2002;99:300-309.
31. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129:559-566.
32. Bosenquet AG, Bell PB. Novel ex vivo analysis of nonclassical pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. Blood. 1996;87:1962-1971.
33. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580-1589.
34. Galcheva-Gargova Z, Derijard B, Wu IH, et al. An osmosensing signal transduction pathway in mammalian cells. Science. 1994;265:806-808.
35. Xia Z, Dichens M, Raingeaud J, et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326-1331.
36. Zhang Y, Huang Y, Rishi AK, et al. Activation of the p38 and JNK/SAPK mitogen-activated protein kinase pathways during apoptosis is mediated by a novel retinoid. Exp Cell Res. 1999;247:233-240.
37. Nick JA, Avdi NJ, Gerwins P, et al. Activation of p38 mitogen-activated protein kinase in human neutrophils by lipopolysaccharide. J Immunol. 1996;156:4867-4875.
38. Anderson SM, Reyland ME, Hunter S, et al. Etoposide-induced activation of c-jun N-terminal kinase (JNK) correlates with drug induced apoptosis in salivary gland acinar cells. Cell Death Differ. 1999;6:454-462.
39. Stadheim TA, Kucera GL. Extracellular signal-regulated kinase (ERK) activity is required for TPA-mediated inhibition of drug-induced apoptosis. Biochem Biophys Res Commun. 1998;245:266-271.
40. Barragan M, Bellosillo B, Campas C, et al. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood. 2002;99:2969-2976.